LT - DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS
EN - DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS
Legal status
Patent not validated
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 39/395 |
|
|
|
A61P 35/02 |
|
|
|
C07K 16/28 |
|
European patent
| (11) |
Number of the document |
2701741 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
12724289.9 |
|
Date of filing the European patent application |
2012-04-30 |
| (97) |
Date of publication of the European application |
2014-03-05 |
| (45) |
Date of publication and mention of the grant of the patent |
2020-06-10
|
| (46) |
Date of publication of the claims translation |
|
PCT application
| (86) |
Number |
PCT/EP2012/001857 |
|
Date |
2012-04-30 |
PCT application publication
| (87) |
Number |
WO 2012/146394 |
|
Date |
2012-11-01 |
Priority applications
| (30) |
Number |
Date |
Country code |
|
201161479961 P |
2011-04-28
|
US |
Inventors
| (72) |
NAGORSEN, Dirk, DE
|
Grantee
| (73) |
Amgen Research (Munich) GmbH,
Staffelseestrasse 2, 81477 München,
DE
|
Title
| (54) |
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS |
| |
DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS |
